Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder
Identifieur interne : 000688 ( PascalFrancis/Corpus ); précédent : 000687; suivant : 000689Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder
Auteurs : M. Berk ; S. Dodd ; M. Kauer-Sant'Anna ; G. S. Malhi ; M. Bourin ; F. Kapczinski ; T. NormanSource :
- Acta psychiatrica scandinavica. Supplementum [ 0065-1591 ] ; 2007.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Objective: Rational therapeutic development in bipolar is hampered by a lack of pathophysiological model. However, there is a wealth of converging data on the role of dopamine in bipolar disorder. This paper therefore examines the possibility of a dopamine hypothesis for bipolar disorder. Method: A literature search was conducted using standard search engines Embase, PyschLIT, PubMed and MEDLINE. In addition, papers and book chapters known to the authors were retrieved and examined for further relevant articles. Results: Collectively, in excess of 100 articles were reviewed from which approximately 75% were relevant to the focus of this paper. Conclusion: Pharmacological models suggest a role of increased dopaminergic drive in mania and the converse in depression. In Parkinson's disease, administration of high-dose dopamine precursors can produce a 'maniform' picture, which switches into a depressive analogue on withdrawal. It is possible that in bipolar disorder there is a cyclical process, where increased dopaminergic transmission in mania leads to a secondary down regulation of dopaminergic receptor sensitivity over time. This may lead to a period of decreased dopaminergic transmission, corresponding with the depressive phase, and the repetition of the cycle. This model, if verified, may have implications for rational drug development.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 08-0007460 INIST |
---|---|
ET : | Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder |
AU : | BERK (M.); DODD (S.); KAUER-SANT'ANNA (M.); MALHI (G. S.); BOURIN (M.); KAPCZINSKI (F.); NORMAN (T.); MALHI (Gin S.); YATHAM (Lakshmi N.) |
AF : | Department of Clinical and Biomedical Sciences, Barwon Health and The Geelong Clinic, University of Melbourne/Geelong, Vic/Australie (1 aut., 2 aut.); Orygen Youth Health/Melbourne, Vic/Australie (1 aut.); Mental Health Research Institute/Melbourne, Vic/Australie (1 aut.); University of British Columbia/Vancouver, BC/Canada (3 aut.); Northern Clinical School, University of Sydney/Sydney, NSW/Australie (4 aut.); CADE Clinic, Department of Psychiatry, Royal North Shore Hospital/Sydney, NSW/Australie (4 aut.); Université de Nantes, EA 3256 -Neurobiologie de l'Anxiété et de la Dépression/Nantes/France (5 aut.); Laboratório de Psiquiatria Molecular, Centro de Pesquisas, Hospital de Clínicas de Porto Alegre/Porto Alegre, RS/Brésil (6 aut.); Department of Psychiatry, University of Melbourne/Melbourne, Vic/Australie (7 aut.); Department of Psychological Medicine, Northern Clinical School, University of Sydney/Sydney/Australie (1 aut.); CADE Clinic, Royal North Shore Hospital/Sydney/Australie (1 aut.); Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital/Sydney/Australie (1 aut.); Mood Disorders Clinical Research Unit, The University of British Columbia/Vancouver, BC/Canada (2 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Acta psychiatrica scandinavica. Supplementum; ISSN 0065-1591; Coden ASSUA6; Royaume-Uni; Da. 2007; Vol. 116; No. 434; Pp. 41-49; Bibl. 77 ref. |
LA : | Anglais |
EA : | Objective: Rational therapeutic development in bipolar is hampered by a lack of pathophysiological model. However, there is a wealth of converging data on the role of dopamine in bipolar disorder. This paper therefore examines the possibility of a dopamine hypothesis for bipolar disorder. Method: A literature search was conducted using standard search engines Embase, PyschLIT, PubMed and MEDLINE. In addition, papers and book chapters known to the authors were retrieved and examined for further relevant articles. Results: Collectively, in excess of 100 articles were reviewed from which approximately 75% were relevant to the focus of this paper. Conclusion: Pharmacological models suggest a role of increased dopaminergic drive in mania and the converse in depression. In Parkinson's disease, administration of high-dose dopamine precursors can produce a 'maniform' picture, which switches into a depressive analogue on withdrawal. It is possible that in bipolar disorder there is a cyclical process, where increased dopaminergic transmission in mania leads to a secondary down regulation of dopaminergic receptor sensitivity over time. This may lead to a period of decreased dopaminergic transmission, corresponding with the depressive phase, and the repetition of the cycle. This model, if verified, may have implications for rational drug development. |
CC : | 002B18C07C |
FD : | Dopamine; Trouble bipolaire; Manie; Etat dépressif; Physiopathologie; Transmission dopaminergique; Psychopharmacologie; Article synthèse; Homme |
FG : | Catécholamine; Neurotransmetteur; Trouble de l'humeur |
ED : | Dopamine; Bipolar disorder; Mania; Depression; Pathophysiology; Dopaminergic transmission; Psychopharmacology; Review; Human |
EG : | Catecholamine; Neurotransmitter; Mood disorder |
SD : | Dopamina; Trastorno bipolar; Mania; Estado depresivo; Fisiopatología; Transmisión dopaminérgica; Psicofarmacología; Artículo síntesis; Hombre |
LO : | INIST-3204B.354000149752300050 |
ID : | 08-0007460 |
Links to Exploration step
Pascal:08-0007460Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder</title>
<author><name sortKey="Berk, M" sort="Berk, M" uniqKey="Berk M" first="M." last="Berk">M. Berk</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Biomedical Sciences, Barwon Health and The Geelong Clinic, University of Melbourne</s1>
<s2>Geelong, Vic</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Orygen Youth Health</s1>
<s2>Melbourne, Vic</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Mental Health Research Institute</s1>
<s2>Melbourne, Vic</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dodd, S" sort="Dodd, S" uniqKey="Dodd S" first="S." last="Dodd">S. Dodd</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Biomedical Sciences, Barwon Health and The Geelong Clinic, University of Melbourne</s1>
<s2>Geelong, Vic</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kauer Sant Anna, M" sort="Kauer Sant Anna, M" uniqKey="Kauer Sant Anna M" first="M." last="Kauer-Sant'Anna">M. Kauer-Sant'Anna</name>
<affiliation><inist:fA14 i1="04"><s1>University of British Columbia</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Malhi, G S" sort="Malhi, G S" uniqKey="Malhi G" first="G. S." last="Malhi">G. S. Malhi</name>
<affiliation><inist:fA14 i1="05"><s1>Northern Clinical School, University of Sydney</s1>
<s2>Sydney, NSW</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>CADE Clinic, Department of Psychiatry, Royal North Shore Hospital</s1>
<s2>Sydney, NSW</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bourin, M" sort="Bourin, M" uniqKey="Bourin M" first="M." last="Bourin">M. Bourin</name>
<affiliation><inist:fA14 i1="07"><s1>Université de Nantes, EA 3256 -Neurobiologie de l'Anxiété et de la Dépression</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kapczinski, F" sort="Kapczinski, F" uniqKey="Kapczinski F" first="F." last="Kapczinski">F. Kapczinski</name>
<affiliation><inist:fA14 i1="08"><s1>Laboratório de Psiquiatria Molecular, Centro de Pesquisas, Hospital de Clínicas de Porto Alegre</s1>
<s2>Porto Alegre, RS</s2>
<s3>BRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Norman, T" sort="Norman, T" uniqKey="Norman T" first="T." last="Norman">T. Norman</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Psychiatry, University of Melbourne</s1>
<s2>Melbourne, Vic</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0007460</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 08-0007460 INIST</idno>
<idno type="RBID">Pascal:08-0007460</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000688</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder</title>
<author><name sortKey="Berk, M" sort="Berk, M" uniqKey="Berk M" first="M." last="Berk">M. Berk</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Biomedical Sciences, Barwon Health and The Geelong Clinic, University of Melbourne</s1>
<s2>Geelong, Vic</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Orygen Youth Health</s1>
<s2>Melbourne, Vic</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Mental Health Research Institute</s1>
<s2>Melbourne, Vic</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dodd, S" sort="Dodd, S" uniqKey="Dodd S" first="S." last="Dodd">S. Dodd</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical and Biomedical Sciences, Barwon Health and The Geelong Clinic, University of Melbourne</s1>
<s2>Geelong, Vic</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kauer Sant Anna, M" sort="Kauer Sant Anna, M" uniqKey="Kauer Sant Anna M" first="M." last="Kauer-Sant'Anna">M. Kauer-Sant'Anna</name>
<affiliation><inist:fA14 i1="04"><s1>University of British Columbia</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Malhi, G S" sort="Malhi, G S" uniqKey="Malhi G" first="G. S." last="Malhi">G. S. Malhi</name>
<affiliation><inist:fA14 i1="05"><s1>Northern Clinical School, University of Sydney</s1>
<s2>Sydney, NSW</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>CADE Clinic, Department of Psychiatry, Royal North Shore Hospital</s1>
<s2>Sydney, NSW</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bourin, M" sort="Bourin, M" uniqKey="Bourin M" first="M." last="Bourin">M. Bourin</name>
<affiliation><inist:fA14 i1="07"><s1>Université de Nantes, EA 3256 -Neurobiologie de l'Anxiété et de la Dépression</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kapczinski, F" sort="Kapczinski, F" uniqKey="Kapczinski F" first="F." last="Kapczinski">F. Kapczinski</name>
<affiliation><inist:fA14 i1="08"><s1>Laboratório de Psiquiatria Molecular, Centro de Pesquisas, Hospital de Clínicas de Porto Alegre</s1>
<s2>Porto Alegre, RS</s2>
<s3>BRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Norman, T" sort="Norman, T" uniqKey="Norman T" first="T." last="Norman">T. Norman</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Psychiatry, University of Melbourne</s1>
<s2>Melbourne, Vic</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Acta psychiatrica scandinavica. Supplementum</title>
<title level="j" type="abbreviated">Acta psychiatr. scand., Suppl.</title>
<idno type="ISSN">0065-1591</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Acta psychiatrica scandinavica. Supplementum</title>
<title level="j" type="abbreviated">Acta psychiatr. scand., Suppl.</title>
<idno type="ISSN">0065-1591</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bipolar disorder</term>
<term>Depression</term>
<term>Dopamine</term>
<term>Dopaminergic transmission</term>
<term>Human</term>
<term>Mania</term>
<term>Pathophysiology</term>
<term>Psychopharmacology</term>
<term>Review</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term>
<term>Trouble bipolaire</term>
<term>Manie</term>
<term>Etat dépressif</term>
<term>Physiopathologie</term>
<term>Transmission dopaminergique</term>
<term>Psychopharmacologie</term>
<term>Article synthèse</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: Rational therapeutic development in bipolar is hampered by a lack of pathophysiological model. However, there is a wealth of converging data on the role of dopamine in bipolar disorder. This paper therefore examines the possibility of a dopamine hypothesis for bipolar disorder. Method: A literature search was conducted using standard search engines Embase, PyschLIT, PubMed and MEDLINE. In addition, papers and book chapters known to the authors were retrieved and examined for further relevant articles. Results: Collectively, in excess of 100 articles were reviewed from which approximately 75% were relevant to the focus of this paper. Conclusion: Pharmacological models suggest a role of increased dopaminergic drive in mania and the converse in depression. In Parkinson's disease, administration of high-dose dopamine precursors can produce a 'maniform' picture, which switches into a depressive analogue on withdrawal. It is possible that in bipolar disorder there is a cyclical process, where increased dopaminergic transmission in mania leads to a secondary down regulation of dopaminergic receptor sensitivity over time. This may lead to a period of decreased dopaminergic transmission, corresponding with the depressive phase, and the repetition of the cycle. This model, if verified, may have implications for rational drug development.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0065-1591</s0>
</fA01>
<fA02 i1="01"><s0>ASSUA6</s0>
</fA02>
<fA03 i2="1"><s0>Acta psychiatr. scand., Suppl.</s0>
</fA03>
<fA05><s2>116</s2>
</fA05>
<fA06><s2>434</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Mania matters</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>BERK (M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DODD (S.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KAUER-SANT'ANNA (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MALHI (G. S.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BOURIN (M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KAPCZINSKI (F.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>NORMAN (T.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>MALHI (Gin S.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>YATHAM (Lakshmi N.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Department of Clinical and Biomedical Sciences, Barwon Health and The Geelong Clinic, University of Melbourne</s1>
<s2>Geelong, Vic</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Orygen Youth Health</s1>
<s2>Melbourne, Vic</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Mental Health Research Institute</s1>
<s2>Melbourne, Vic</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>University of British Columbia</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Northern Clinical School, University of Sydney</s1>
<s2>Sydney, NSW</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>CADE Clinic, Department of Psychiatry, Royal North Shore Hospital</s1>
<s2>Sydney, NSW</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Université de Nantes, EA 3256 -Neurobiologie de l'Anxiété et de la Dépression</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Laboratório de Psiquiatria Molecular, Centro de Pesquisas, Hospital de Clínicas de Porto Alegre</s1>
<s2>Porto Alegre, RS</s2>
<s3>BRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Psychiatry, University of Melbourne</s1>
<s2>Melbourne, Vic</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Department of Psychological Medicine, Northern Clinical School, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>CADE Clinic, Royal North Shore Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="03"><s1>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="04"><s1>Mood Disorders Clinical Research Unit, The University of British Columbia</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s1>41-49</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>3204B</s2>
<s5>354000149752300050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>77 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0007460</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Acta psychiatrica scandinavica. Supplementum</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective: Rational therapeutic development in bipolar is hampered by a lack of pathophysiological model. However, there is a wealth of converging data on the role of dopamine in bipolar disorder. This paper therefore examines the possibility of a dopamine hypothesis for bipolar disorder. Method: A literature search was conducted using standard search engines Embase, PyschLIT, PubMed and MEDLINE. In addition, papers and book chapters known to the authors were retrieved and examined for further relevant articles. Results: Collectively, in excess of 100 articles were reviewed from which approximately 75% were relevant to the focus of this paper. Conclusion: Pharmacological models suggest a role of increased dopaminergic drive in mania and the converse in depression. In Parkinson's disease, administration of high-dose dopamine precursors can produce a 'maniform' picture, which switches into a depressive analogue on withdrawal. It is possible that in bipolar disorder there is a cyclical process, where increased dopaminergic transmission in mania leads to a secondary down regulation of dopaminergic receptor sensitivity over time. This may lead to a period of decreased dopaminergic transmission, corresponding with the depressive phase, and the repetition of the cycle. This model, if verified, may have implications for rational drug development.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B18C07C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Trouble bipolaire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Bipolar disorder</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Trastorno bipolar</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Manie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Mania</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Mania</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Depression</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Physiopathologie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Pathophysiology</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Fisiopatología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Transmission dopaminergique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopaminergic transmission</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Transmisión dopaminérgica</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Psychopharmacologie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Psychopharmacology</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Psicofarmacología</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Review</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>18</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>39</s5>
</fC07>
<fN21><s1>007</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 08-0007460 INIST</NO>
<ET>Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder</ET>
<AU>BERK (M.); DODD (S.); KAUER-SANT'ANNA (M.); MALHI (G. S.); BOURIN (M.); KAPCZINSKI (F.); NORMAN (T.); MALHI (Gin S.); YATHAM (Lakshmi N.)</AU>
<AF>Department of Clinical and Biomedical Sciences, Barwon Health and The Geelong Clinic, University of Melbourne/Geelong, Vic/Australie (1 aut., 2 aut.); Orygen Youth Health/Melbourne, Vic/Australie (1 aut.); Mental Health Research Institute/Melbourne, Vic/Australie (1 aut.); University of British Columbia/Vancouver, BC/Canada (3 aut.); Northern Clinical School, University of Sydney/Sydney, NSW/Australie (4 aut.); CADE Clinic, Department of Psychiatry, Royal North Shore Hospital/Sydney, NSW/Australie (4 aut.); Université de Nantes, EA 3256 -Neurobiologie de l'Anxiété et de la Dépression/Nantes/France (5 aut.); Laboratório de Psiquiatria Molecular, Centro de Pesquisas, Hospital de Clínicas de Porto Alegre/Porto Alegre, RS/Brésil (6 aut.); Department of Psychiatry, University of Melbourne/Melbourne, Vic/Australie (7 aut.); Department of Psychological Medicine, Northern Clinical School, University of Sydney/Sydney/Australie (1 aut.); CADE Clinic, Royal North Shore Hospital/Sydney/Australie (1 aut.); Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital/Sydney/Australie (1 aut.); Mood Disorders Clinical Research Unit, The University of British Columbia/Vancouver, BC/Canada (2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Acta psychiatrica scandinavica. Supplementum; ISSN 0065-1591; Coden ASSUA6; Royaume-Uni; Da. 2007; Vol. 116; No. 434; Pp. 41-49; Bibl. 77 ref.</SO>
<LA>Anglais</LA>
<EA>Objective: Rational therapeutic development in bipolar is hampered by a lack of pathophysiological model. However, there is a wealth of converging data on the role of dopamine in bipolar disorder. This paper therefore examines the possibility of a dopamine hypothesis for bipolar disorder. Method: A literature search was conducted using standard search engines Embase, PyschLIT, PubMed and MEDLINE. In addition, papers and book chapters known to the authors were retrieved and examined for further relevant articles. Results: Collectively, in excess of 100 articles were reviewed from which approximately 75% were relevant to the focus of this paper. Conclusion: Pharmacological models suggest a role of increased dopaminergic drive in mania and the converse in depression. In Parkinson's disease, administration of high-dose dopamine precursors can produce a 'maniform' picture, which switches into a depressive analogue on withdrawal. It is possible that in bipolar disorder there is a cyclical process, where increased dopaminergic transmission in mania leads to a secondary down regulation of dopaminergic receptor sensitivity over time. This may lead to a period of decreased dopaminergic transmission, corresponding with the depressive phase, and the repetition of the cycle. This model, if verified, may have implications for rational drug development.</EA>
<CC>002B18C07C</CC>
<FD>Dopamine; Trouble bipolaire; Manie; Etat dépressif; Physiopathologie; Transmission dopaminergique; Psychopharmacologie; Article synthèse; Homme</FD>
<FG>Catécholamine; Neurotransmetteur; Trouble de l'humeur</FG>
<ED>Dopamine; Bipolar disorder; Mania; Depression; Pathophysiology; Dopaminergic transmission; Psychopharmacology; Review; Human</ED>
<EG>Catecholamine; Neurotransmitter; Mood disorder</EG>
<SD>Dopamina; Trastorno bipolar; Mania; Estado depresivo; Fisiopatología; Transmisión dopaminérgica; Psicofarmacología; Artículo síntesis; Hombre</SD>
<LO>INIST-3204B.354000149752300050</LO>
<ID>08-0007460</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000688 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000688 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:08-0007460 |texte= Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |